- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Merus NV (2GH)Merus NV stock price live, this page displays NASDAQ MRUS stock exchange data. View the MRUS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Merus NV real time stock price chart below.
What Is the Merus NV Stock Price Today?
The Merus NV stock price today is 38.80.
What Is the Stock Symbol for Merus NV?
The stock symbol for Merus NV is "MRUS."
What Stock Exchange Does Merus NV Trade On?
Merus NV is listed and trades on the NASDAQ stock exchange.
Is Merus NV a Good Stock to Buy?
Determining whether Merus NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MRUS quote. (ISIN: NL0011606264)
What Is the Merus NV Stock Price Today?
The Merus NV stock price today is 38.80.
What Is the Stock Symbol for Merus NV?
The stock symbol for Merus NV is "MRUS."
What Stock Exchange Does Merus NV Trade On?
Merus NV is listed and trades on the NASDAQ stock exchange.
Is Merus NV a Good Stock to Buy?
Determining whether Merus NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MRUS quote. (ISIN: NL0011606264)
38.80
-1.60(-3.96%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
38.80
39.00
52 wk Range
22.40
55.50
2GH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
38.8039.00
52 wk Range
22.4055.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2GH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
86.07
Upside
+100.96%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Merus N.V. Announces FDA Approval of BIZENGRI
- Investing.com
- Merus BV receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Merus BV receives Investment Bank Analyst Rating Update
- Investing.com
Pro - FDA approves first NRG1+ therapy for certain cancers
- Investing.com
- Merus N.V. Announces FDA Approval of BIZENGRI
- Investing.com
Merus NV Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Compare 2GH to Peers and Sector
Metrics to compare | 2GH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2GHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.6x | −4.5x | −0.6x | |
PEG Ratio | 1.16 | 0.01 | 0.00 | |
Price/Book | 4.0x | 2.5x | 2.6x | |
Price / LTM Sales | 79.0x | 22.2x | 3.2x | |
Upside (Analyst Target) | - | 220.3% | 49.4% | |
Fair Value Upside | Unlock | 15.5% | 7.8% | Unlock |
People Also Watch
FAQ
What Is the Merus (2GH) Stock Price Today?
The Merus stock price today is 38.80
What Stock Exchange Does Merus Trade On?
Merus is listed and trades on the Frankfurt stock exchange.
What Is the Stock Symbol for Merus?
The stock symbol for Merus is "2GH."
What Is the Merus Market Cap?
As of today, Merus market cap is 2.78B.
What is Merus Earnings Per Share?
The Merus EPS is -3.98.
From a Technical Analysis Perspective, Is 2GH a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.